Scarica l'app Stockscreener
52.45
1.34%
-0.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$53.16
Aprire:
$53.56
Volume 24 ore:
927.11K
Relative Volume:
2.07
Capitalizzazione di mercato:
$2.52B
Reddito:
$307.03M
Utile/perdita netta:
$-99.81M
Rapporto P/E:
-25.34
EPS:
-2.0695
Flusso di cassa netto:
$-27.20M
1 W Prestazione:
+4.82%
1M Prestazione:
+9.32%
6M Prestazione:
+27.18%
1 anno Prestazione:
+85.40%
Intervallo 1D:
$52.05
$54.23
Intervallo di 1 settimana:
$49.48
$54.23
Portata 52W:
$23.14
$54.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Confronta MIRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
52.45 | 2.52B | 307.03M | -99.81M | -27.20M | -2.0695 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum’s Ctexli wins FDA nod in cerebrotendinous xanthomatosis - BioWorld Online
US FDA approves Mirum Pharma's genetic disorder drug - Reuters.com
Mirum Pharmaceuticals' Lipid Storage Disease Treatment Gets FDA Approval -February 21, 2025 at 01:48 pm EST - Marketscreener.com
US FDA approves Mirum Pharma’s genetic disorder drug - KFGO
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease -February 21, 2025 at 01:20 pm EST - Marketscreener.com
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol - Benzinga
Mirum gains FDA approval of chenodiol for rare lipid storage disease - Seeking Alpha
FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease - MarketWatch
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 11:54 am EST - Marketscreener.com
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 - BioSpace
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 20 - WICZ
Mirum Pharma's Critical Q4 Earnings Call: Will 2024 Results Signal Growth Momentum? - StockTitan
High Growth Tech Stocks in United States to Watch - Simply Wall St
Mirum Pharmaceuticals stock soars to all-time high of $53.52 - Investing.com India
Mirum Pharmaceuticals stock soars to all-time high of $53.52 By Investing.com - Investing.com Nigeria
How to Take Advantage of moves in (MIRM) - Stock Traders Daily
Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Alagille Syndrome Market Expected to rise, 2034 | Mirum Pharmaceuticals, Albireo, expected to drive market - Barchart
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharma (MIRM) Unveils Strategic Talent Package: 74K Shares in Equity Grants - StockTitan
SG Americas Securities LLC Sells 13,575 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 1,064 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Hits New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares - MarketBeat
(MIRM) Technical Pivots with Risk Controls - Stock Traders Daily
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Golden State Equity Partners Has $801,000 Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Genomenon and Mirum Pharmaceuticals Join Forces to Enhance CTX Disease Awareness and Diagnosis - PR Web
Mirum Pharmaceuticals president sells $126,680 in stock - MSN
Mirum Pharmaceuticals (NASDAQ:MIRM) shareholder returns have been solid, earning 192% in 5 years - Simply Wall St
Major Insider Stock Sales at Mirum Pharmaceuticals! - TipRanks
Mirum Pharmaceuticals president sells $126,680 in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Mirum Pharmaceuticals stock soars to all-time high of $49.59 - MSN
First Week of MIRM March 21st Options Trading - Nasdaq
Mirum Pharmaceuticals stock soars to all-time high of $49.59 By Investing.com - Investing.com UK
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why - Yahoo Finance
Mirum Pharmaceuticals SVP sells shares worth $43,227 By Investing.com - Investing.com Australia
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of Stock - MarketBeat
Christopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock - MarketBeat
Mirum Pharmaceuticals CEO sells shares worth $327,658 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mirum Pharmaceuticals Inc Azioni (MIRM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Feb 03 '25 |
Sale |
48.22 |
9,102 |
438,921 |
115,920 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Feb 03 '25 |
Sale |
48.22 |
1,064 |
51,309 |
4,232 |
| Radovich Peter | PRESIDENT AND COO |
Jan 24 '25 |
Sale |
47.92 |
3,177 |
152,256 |
29,588 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jan 24 '25 |
Sale |
47.92 |
902 |
43,228 |
3,524 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jan 24 '25 |
Sale |
47.92 |
6,837 |
327,658 |
125,022 |
| Quan Joanne | CHIEF MEDICAL OFFICER |
Jan 17 '25 |
Sale |
45.86 |
6,969 |
319,598 |
5,649 |
| Radovich Peter | PRESIDENT AND COO |
Jan 07 '25 |
Sale |
42.82 |
1,998 |
85,545 |
27,015 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Jan 07 '25 |
Sale |
42.82 |
7,489 |
320,644 |
119,359 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Jan 07 '25 |
Sale |
42.82 |
750 |
32,111 |
2,926 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Nov 14 '24 |
Option Exercise |
2.94 |
2,500 |
7,350 |
4,926 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):